Quarterly report · Q1
2372.TEDINET S100RJUD
Period2023-04-01 → 2023-06-30
Filed2023-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.7bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥18.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥737m | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥1.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.1bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.2bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.5bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥891m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥891m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥36.1bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥35.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥28.2bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥23.3bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥23.0bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥12.8bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥12.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.0bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.5bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥73.66 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥88.37 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥210.06 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥88.22 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 35.3% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.9% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-06-30 | ¥86m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥70m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥15m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-06-30 | −¥212m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥774m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥774m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥328m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥875m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥605m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥269m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥190m |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥1.6bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥1.4bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥137m |
| jpcrp040300-q1r_E05352-000CROreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥36m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥453m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥277m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥176m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥49m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥2.3bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥174m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥1.1bn |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥5.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥4.6bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥758m |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥5.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥4.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥774m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥23m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥19m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | −¥45m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥357m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥357m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥364m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥370m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥359m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥10m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥40m |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥75m |
| jpcrp040300-q1r_E05352-000CROreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥61m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥483m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥256m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥226m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥38m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥24m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.7bn |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥337m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥357m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 402
| Item | Context | Value | Unit |
|---|---|---|---|
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |